TrialThe oncologist2021

Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study.

Ye Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.